Heartburn

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Vonoprazan/amoxicillin, Table, FDA, DTC, Pharmacy, Gastrointestinal disease, NERD, NDA, Hercules, Amazon Prime Video, Food, Research, Webcast, Business, Forecasting, Prescription, Cigna, PPI, PDUFA, Tablet, Patient, Physician, Ratio, Enzyme inhibitor, DDW, Marketing, Vonoprazan/amoxicillin/clarithromycin, Heartburn, Hulu, GERD, Clinical trial, GAAP, Growth, Overalls, Eosinophilic esophagitis, Pharmaceutical industry

ET

Key Points: 
  • ET
    FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
  • Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Lucid Diagnostics Partners with the Esophageal Cancer Action Network (ECAN) to Highlight Esophageal Cancer Awareness Month

Retrieved on: 
Lunedì, Aprile 29, 2024
Education, Risk, Esophageal cancer, ECAN, Lucid, Research, Human, Heartburn, GERD

NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.

Key Points: 
  • NEW YORK, April 29, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.
  • ECAN, a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research, was founded 15 years ago by Mindy Mintz Mordecai following the tragic death of her husband of esophageal cancer.
  • Lucid and ECAN are partnering to spread the potentially life-saving message that heartburn (also known as acid reflux or GERD) can lead to highly lethal esophageal cancer and that esophageal cancer is preventable through early precancer detection.
  • "This is our 15th Esophageal Cancer Awareness Month, and we are thrilled to see so many companies and individuals paying attention and advocating for early, proactive screening.

Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues

Retrieved on: 
Mercoledì, Aprile 24, 2024
Research, Biotechnology, Other Health, Alternative Medicine, Health, Pharmaceutical, General Health, Other Science, Science, USD, CVS, Target, Walmart, Nature, Meal, Food, Nausea, Stomach, Digestate, Growth, Bloating, Plant, Amazon, Disease, Patient, Trust, Multimedia, Peppermint, Heartburn, Ageing

Iberogast helps reduce stomach acid, regulate stomach muscles, calm gut nerves, and support both the gut lining and microbiome.

Key Points: 
  • Iberogast helps reduce stomach acid, regulate stomach muscles, calm gut nerves, and support both the gut lining and microbiome.
  • *
    Caraway helps relax certain intestinal muscles, reduces acidity in the stomach and helps relieve occasional indigestion when combined with peppermint.
  • “With tens of millions of Americans experiencing occasional digestive health issues, this clinically proven, game-changing product will allow them to experience the power of nature and its incredible abilities to support gut health.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Too Much Acid in Your Diet: It's Probably Your Coffee

Retrieved on: 
Mercoledì, Aprile 24, 2024
Coffee, A&T, NIH, University of California, Davis, Research, Acid, Bloating, NC A&T, Reflux, Critical, Heartburn, UC

This is important, as the high acid levels in regular coffee are now known to cause gut and other health problems.

Key Points: 
  • This is important, as the high acid levels in regular coffee are now known to cause gut and other health problems.
  • Coffee is a well-known source of acid and health problems; WebMD.com lists coffee as the leading cause of heartburn, and Leena Khaitan , MD states, "…the worst beverage for Acid Reflux is coffee".
  • Mislabeling by certain coffee brands claiming low acid is a growing concern, particularly in light of the serious health risks coming from high acid diets.
  • More on acid in coffee, and on Puroast verified low acid quality, and as an option to conventional high acid coffees, can be found at www.puroast.com .

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Martedì, Marzo 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Rolaids® Bolsters Presence in Convenience Stores Through Strategic Partnership with Lil’ Drug Store Products

Retrieved on: 
Mercoledì, Marzo 27, 2024
Women, Supermarket, Convenience Store, Other Health, General Health, Pharmaceutical, Consumer, Health, Cosmetics, Retail, LDSP, Partnership, Smoker, Acquisition, Heartburn, Marketing, P&G, Procter & Gamble, Advertising

Lil’ Drug Store Products (LDSP) announces a strategic partnership with Procter & Gamble (P&G) for the preferred distribution of Rolaids® – the trusted heartburn relief brand – to convenience and travel retailers nationwide.

Key Points: 
  • Lil’ Drug Store Products (LDSP) announces a strategic partnership with Procter & Gamble (P&G) for the preferred distribution of Rolaids® – the trusted heartburn relief brand – to convenience and travel retailers nationwide.
  • Following P&G’s acquisition of Rolaids, LDSP has emerged as the primary distributor, leading the reintroduction of its diverse product range into key retail channels.
  • This collaboration solidifies LDSP's pivotal role as the convenience distributor of choice for Rolaids, further reinforcing its position as a category leader in the industries it serves.
  • With approximately 45% of heartburn sufferers also identifying as smokers, this underscores the vital role of convenience stores in reaching many individuals experiencing heartburn.

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Retrieved on: 
Martedì, Marzo 12, 2024
Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Apps, Applications, Partnership, Patient, Irritable bowel syndrome, Acquisition, CBT, Heartburn, Digestate, IBD, Bayer, Patient satisfaction, Cognitive behavioral therapy, Therapy, IBS, Lux Capital, FDA, Digestive, Coeliac disease, Gesellschaft mit beschränkter Haftung, Nursing

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Key Points: 
  • Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.
  • The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
  • Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
  • "The combination of Mahana and Cara Care is an incredible opportunity to bring together our complementary expertise in chronic digestive health conditions and create a one-of-a-kind global offering of digital programs across the Digestive, Hearing, Dermatology, and Women’s Health markets.

Advisory - Only use authorized nicotine pouches as directed, and do not use unauthorized nicotine pouches

Retrieved on: 
Mercoledì, Marzo 20, 2024
Palpitations, Varenicline, Chest pain, Xerostomia, Dizziness, Weakness, Caregiver, Nervous, Indigestion, Sleep, Risk, Headache, NPN, Health, Nicotine, Angina, Internet, Stroke, Constipation, Smoke, Death, Heartburn, Health Canada, Arrhythmia, Nausea, Medicine, Nursing, Safety, Fatigue, Vomiting, Blurred vision, Allergy, Parent, Chronic pain, Advertising, Tobacco

Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.

Key Points: 
  • Consuming multiple nicotine products at the same time, including authorized nicotine replacement therapy products, or varenicline (a prescription smoking cessation drug), may increase the adverse effects of nicotine.
  • Use authorized nicotine pouches only as directed:
    To date, Health Canada has authorized only one nicotine pouch , containing 4 mg of nicotine per dose.
  • Nicotine replacement therapies, including nicotine pouches, are not authorized for recreational use or for use by nonsmokers and people under 18 years old.
  • There are no authorized nicotine pouches in Canada that contain more than 4 mg of nicotine per dose.

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Retrieved on: 
Mercoledì, Aprile 3, 2024
Asteraceae, Ethanol, Artichoke, Diarrhea, Cardoon, Spasm, Patient, Physiology, Monograph, Committee, Flatulence, Herbal medicine, Heartburn, Date, Allergy, Plant, Nausea, Sensation, Mouth, Water, Bloating, Liver, Bile, Medicine, Dietary supplement

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Marzo 7, 2024
Esophagus, Hercules, Pharmacy, Quarter, Research, Heartburn, DUAL, Regulation, Forecasting, FDA, Pain, Table, PDUFA, Vomiting, Inflammation, GERD, Ratio, PPI, GAAP, Business, Webcast, Enzyme inhibitor, Patient, Express Scripts, Helicobacter pylori, Clinical trial, Vonoprazan/amoxicillin, PBM, G&A, Eosinophilic esophagitis, Tablet, NDA, Prescription, Vonoprazan/amoxicillin/clarithromycin, Pharmaceutical industry

Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.

Key Points: 
  • Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.
  • Fourth quarter 2023 net loss included a non-cash charge related to stock-based compensation of $24.6 million compared to $6.7 million for fourth quarter 2022.
  • Phathom will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results and business highlights today, March 7, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.